Results 51 to 60 of about 35,440 (172)

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Sunitinib resistance in renal cell carcinoma

Journal of Kidney Cancer and VHL, 2014
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC).
Christudas Morais
doaj   +1 more source

Microbiome—pancreatic cancer crosstalk: From tumor biology to therapeutic intervention

iMetaOmics, EarlyView.
The intratumoral microbiome acts as a critical regulator in pancreatic cancer progression and therapeutic resistance. This comprehensive review delineates the origins of pancreatic microbes, elucidates their multifaceted mechanisms in driving immune suppression, metabolic reprogramming, and stromal desmoplasia, and highlights the clinical potential of ...
Yuqin Xie, Jingyuan Ye, Sheng Wang, Maoyun Liu, Fengsheng Dai, Mingzhen Bai, Yi Wang, Athena Savoji, Yu Wang, Phillip B. Hylemon, Huiping Zhou, Hui Li, Dewei Li   +12 more
wiley   +1 more source

EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation

EBioMedicine, 2019
Background: Sunitinib is one of the multi-targeted tyrosine kinase inhibitors for the treatment of renal cell carcinoma (RCC) at present. However, its clinical efficacy is limited by chemoresistance of RCC.
Hai Huang, Yi Gao, Ao Liu, Xiaoqun Yang, Fang Huang, Le Xu, Xu Danfeng, Lu Chen   +7 more
doaj   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

Journal of Applied Toxicology, EarlyView.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü, Münevver Baran, Miyase Gözde Gündüz, Şengül Dilem Doğan   +3 more
wiley   +1 more source

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

Contemporary Oncology, 2016
Aim of the study : Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug. Material and methods : Data on mRCC patients were obtained from the hospital archives.
Çetin Ordu, Kezban N. Pilanci, Nilüfer Avcı, İbrahim Yıldız, Gül Alço, Özkan Demirhan, Ülkühan I. Köksal, Filiz Elbüken, Coskun Tecimer, Gökhan Demir   +9 more
doaj   +1 more source

Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application

Journal of Surgical Oncology, EarlyView.
ABSTRACT Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers.
Kristin E. Goodsell, Jason A. Carter, Hannah R. Abrams, Harveshp Mogal, Elizabeth T. Loggers, Jeremy Sharib   +5 more
wiley   +1 more source

Ultra‐High Frequency Ultrasound Imaging and Quantification of Microvascular Flow in Xenograft Renal Cell Carcinoma in an Avian Chorioallantoic Membrane Model

Journal of Ultrasound in Medicine, EarlyView.
Patient‐derived xenograft (PDX) tumor models initiated in avian chorioallantoic membranes (CAM) are under investigation to evaluate the effectiveness of therapeutic options with the objective of personalizing treatments. CAM PDXs paired with ultra‐high frequency ultrasound (UHFUS) imaging could potentially constitute prospective high throughput assays ...
Sara Mar, Emmanuel Chérin, Justin Xu, David E. Goertz, Hon S. Leong, Christine E.M. Demore   +5 more
wiley   +1 more source

A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma

Journal of Nanobiotechnology
Background Sunitinib is a multikinase inhibitor used to treat patients with advanced renal cell carcinoma (RCC). However, sunitinib toxicity makes it a double-edged sword. Potent immune modulation by sunitinib extends to nuclear interactions.
Po-Fu Yueh, Chih-Sheng Chiang, I-Jung Tsai, Yun-Long Tseng, He-Ru Chen, Keng-Li Lan, Fei-Ting Hsu   +6 more
doaj   +1 more source

PRDM1 Knockdown Promotes Ferroptosis and Sunitinib Sensitivity by Modulating the PI3K/Akt Signaling Through Inhibition of ESM1 Transcription in Renal Cell Carcinoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Renal cell carcinoma (RCC) is a commonly occurring and considerable burden on public health. Although chemotherapy benefits patients with advanced RCC, sunitinib resistance leads to a poor prognosis. Ferroptosis is also involved in sunitinib resistance in RCC.
Yi‐Shuai Zhang, Xin‐Qi Pei, Ji‐Ping Sun, Chen‐Hui Ma, Xin‐Yang Wang, Xu‐Dong Li   +5 more
wiley   +1 more source